Superluminal Medicines Raises $120 Million to Advance GPCR-Targeted Drug Discovery

Superluminal Medicines, Inc. has raised $120 million in a Series A funding round led by RA Capital Management, with participation from Insight Partners, NVentures, Catalio Capital Management, Eli Lilly and Company, Gaingels, and Cooley LLP. The funding will be directed towards advancing Superluminal’s lead programs into clinical development and expanding its pipeline of small molecule drugs targeting G protein-coupled receptors (GPCRs).

Superluminal’s platform combines generative biology, chemistry, machine learning, and proprietary data infrastructure to create candidate-ready compounds. The technology focuses on GPCRs, a major class of drug targets involved in cell signaling. Despite their importance, many GPCRs remain undrugged due to the complexity of their structures and functions.

The platform aims to address this challenge by modeling protein dynamics to identify specific conformations associated with disease states, which can be targeted more precisely.

Cony D'Cruz, CEO of Superluminal Medicines, explained the company’s approach:

“Our approach allows us to interrogate proteins dynamically, exploring the variety of conformations a protein can adopt, which is critical to identifying specific disease states mediated by membrane receptors. By understanding and leveraging these dynamic properties, we can intervene positively within the natural context of the cell and the body.”

Superluminal’s technology uses a predict-design-test model that integrates deep biological and chemical expertise with machine learning to design highly selective compounds. This method is intended to improve the speed and accuracy of identifying and optimizing drug candidates, especially for complex targets like GPCRs, which currently represent approximately 35% of approved drug targets but have many potential therapeutic opportunities that remain unexplored.

Andrew Levin, MD, PhD, Partner and Managing Director at RA Capital Management, highlighted the platform's progress:

“We continue to be impressed by the speed at which Superluminal has progressed its existing programs for really challenging drug targets. Superluminal’s platform and team have demonstrated success, and we are pleased to continue to support the company’s further growth and development.”

The funding will also support the enhancement of Superluminal’s proprietary platform, which integrates in silico pharmacokinetic and toxicology prediction capabilities, aiming to streamline the drug discovery process further. The company plans to expand its efforts to target other membrane proteins, including ion channels and transporters, broadening its pipeline of small molecule therapeutics.

Topic: Biotech Ventures